Apr, 2018

Global
News / Media
TOKYO, April 18, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, “Astellas” ) and Kite, a Gilead Company (Nasdaq: GILD, President and CEO: John Milligan, “Kite”) today announced that an agreement has been completed for the transfer of certain Agensys research facilities in Santa Monica, California, USA, to Kite. The asset transfer was completed on April 12, 2018. Additio...
Read More

Mar, 2018

Global
News / Media
Tokyo, March 29, 2018 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced an agreement for collaborative research with the Drugs for Neglected Diseases initiative1 (DNDi) and seven other pharmaceutical companies2 in a consortium called Neglected Tropical Diseases (NTD) Drug Discovery Booster. The consortium is supported by funding from the Global Health Innov...
Read More
Global
News / Media
TOKYO and BOTHELL, Wash., – March 26, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to enfortumab vedotin, an antibody-drug conjugate (ADC), for patients with locally advanced or metastatic urothelial ca...
Read More
Global
News / Media
Tokyo, March 26, 2018  - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “the Company”) announced that it completed acquisition of its own shares, which was resolved by its Board of Directors on January 31, 2018, pursuant to Article 156 which is applicable in accordance with Article 165, paragraph 3 of the Companies Act. Particulars 1. Class of shares acquired:  Common st...
Read More
Nothing Found

Unfortunately, we weren't able to find a match for your search query. Please try again.

Nothing Found

Unfortunately, we weren't able to find a match for your search query. Please try again.

Nothing Found

Unfortunately, we weren't able to find a match for your search query. Please try again.